Molecular PartnersMOLN
About: Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
Employees: 159
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
306% more capital invested
Capital invested by funds: $4.2M [Q3] → $17M (+$12.8M) [Q4]
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
6.56% more ownership
Funds ownership: 2.31% [Q3] → 8.88% (+6.56%) [Q4]
0% more funds holding
Funds holding: 5 [Q3] → 5 (+0) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
LifeSci Capital | 186%upside $12 | Outperform Initiated | 11 Mar 2025 |
Financial journalist opinion
Based on 3 articles about MOLN published over the past 30 days









